Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Supernus Pharm (NQ: SUPN ) 36.18 -1.59 (-4.21%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Supernus Pharm < Previous 1 2 3 4 5 Next > Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference November 13, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Third Quarter 2024 Financial Results November 04, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 October 31, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results October 21, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder October 17, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder October 10, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree September 24, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit September 19, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug September 11, 2024 Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million. Via Benzinga This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday September 11, 2024 Via Benzinga Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday September 11, 2024 Via Benzinga Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference August 28, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA August 19, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Second Quarter 2024 Financial Results August 06, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals. August 06, 2024 In a market where value is scarce, SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) offers a refreshing opportunity with its solid fundamentals. Via Chartmill Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device August 01, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 July 23, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names July 19, 2024 Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. Via InvestorPlace NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. July 05, 2024 SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill Trading SMID Biotech Stocks In A Volatile Market July 01, 2024 Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... Via Talk Markets Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents. June 14, 2024 SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) stands out as a stock that provides good value for the fundamentals it showcases. Via Chartmill Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy May 23, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures May 09, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024 May 08, 2024 SUPN stock results show that Supernus Pharmaceuticals missed on revenue for the first quarter of 2024. Via InvestorPlace Supernus Announces First Quarter 2024 Financial Results May 08, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors May 02, 2024 From Glancy Prongay & Murray LLP Via Business Wire INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors May 01, 2024 From Law Offices of Howard G. Smith Via Business Wire Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story May 01, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors April 29, 2024 From The Law Offices of Frank R. Cruz Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
